The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Will ctDNA replace pathologic complete response in NSCLC?
Atocha Romero, PharmD, PhD, Hospital Universitario Puerta de Hierro, Madrid, Spain, discusses whether circulating tumor DNA (ctDNA) will replace pathologic complete response (pCR) in non-small cell lung cancer (NSCLC). Dr Romero believes ctDNA will not replace pCR but rather complement it. ctDNA may aid in answering questions surrounding the adjuvant settings and the management of patients following neoadjuvant chemotherapy and surgery. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
